Trials / Completed
CompletedNCT00264160
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, multicenter trial will evaluate the efficacy and safety of treatment with AMN107 in chronic myelogenous leukemia (CML) patients that are resistant and/or intolerant to imatinib mesylate therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMN107 |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-11-01
- Completion
- 2009-08-01
- First posted
- 2005-12-12
- Last updated
- 2017-03-06
Locations
4 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT00264160. Inclusion in this directory is not an endorsement.